Levamlodipine: Drug information

(For additional information see "Levamlodipine: Patient drug information" and see "Levamlodipine: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

Brand Names: US

Conjupri

Pharmacologic Category

Antihypertensive;
Calcium Channel Blocker;
Calcium Channel Blocker, Dihydropyridine

Dosing: Adult

Hypertension

Hypertension:

Note: For initial treatment in patients with BP ≥20/10 mm Hg above goal, may be used in combination with another appropriate agent (eg, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, thiazide diuretic). For patients <20/10 mm Hg above goal, some experts recommend an initial trial of monotherapy; however, over time, many patients will require combination therapy (Ref).

Oral: Initial: 1.25 to 2.5 mg once daily; titrate every 1 to 2 weeks as needed based on patient response; maximum: 5 mg/day. Antihypertensive effect attenuates with higher doses and adverse effects may become more prominent (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

No dosage adjustment necessary.

Dosing: Hepatic Impairment: Adult

Hypertension: Initial: 1.25 mg once daily; titrate slowly in patients with severe hepatic impairment.

Dosing: Older Adult

Note: Dosing should start at the lower end of dosing range and be titrated to response due to possible increased incidence of hepatic, renal, or cardiac impairment. Elderly patients also show decreased clearance of amlodipine.

Hypertension: Oral: Initial: 1.25 mg once daily.

Dosing: Pediatric

(For additional information see "Levamlodipine: Pediatric drug information")

Hypertension

Hypertension: Children and Adolescents 6 to ≤17 years: Oral: 1.25 to 2.5 mg once daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children and Adolescents 6 to ≤17 years: No dosage adjustment necessary in kidney impairment.

Dosing: Hepatic Impairment: Pediatric

There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment and slow titration are suggested.

Adverse Reactions (Significant): Considerations

All adverse reactions were reported with amlodipine, as levamlodipine is the pharmacologically active isomer of amlodipine.

Peripheral edema

Peripheral edema is the most common adverse reaction with amlodipine, characterized by ankle and leg swelling independent of fluid retention (Ref). It is a bothersome adverse reaction for patients and may lead to discontinuation (Ref). Peripheral edema can be expected to subside within several days following intervention.

Mechanism: Dose- and time-related; related to the pharmacologic action. Calcium channel blocker-mediated peripheral edema is caused by arteriolar vasodilation that subsequently leads to increased hydrostatic pressure in the precapillary circulation and fluid movement from the capillary vasculature to the interstitial space (Ref). In addition, impaired postural vasoconstriction may contribute (Ref).

Risk factors:

• Dose; generally greater with higher doses (Ref); however, may develop more frequently and at lower doses in patients with impaired postural autoregulation (eg, diabetes, arterial disease) (Ref)

• Duration-related (Ref)

• Females

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. All adverse reactions were reported with amlodipine, as levamlodipine is the pharmacologically active isomer of amlodipine.

>10%: Cardiovascular: Peripheral edema (2% to 11%, dose-related; females: 15%; males: 6%) (table 1)

**Levamlodipine: Adverse Reaction: Peripheral Edema**
Drug (Levamlodipine)	Placebo	Population	Dose	Number of Patients (Levamlodipine)	Number of Patients (Placebo)	Comments
15%	5%	Females	N/A	512	336	Reported with amlodipine, as levamlodipine is the pharmacologically active isomer of amlodipine
6%	1%	Males	N/A	1,218	914
11%	0.6%	N/A	10 mg/day	268	520
3%	0.6%	N/A	5 mg/day	296	520
2%	0.6%	N/A	2.5 mg/day	275	520

1% to 10%:

Cardiovascular: Flushing (≤3%; dose-related, more frequent in females), palpitations (1% to 5%; dose-related, more frequent in females)

Gastrointestinal: Abdominal pain (2%), nausea (3%)

Nervous system: Dizziness (doses ≥5 mg/day: 3%), drowsiness (1%), fatigue (5%)

<1%:

Cardiovascular: Peripheral ischemia, sinus tachycardia, syncope, vasculitis

Dermatologic: Diaphoresis, erythema multiforme, pruritus, skin rash

Endocrine & metabolic: Hot flash, hyperglycemia, weight gain, weight loss

Gastrointestinal: Anorexia, constipation, dysphagia, flatulence, gingival hyperplasia, pancreatitis, vomiting, xerostomia

Genitourinary: Nocturia, urinary frequency

Hematologic & oncologic: Leukopenia, purpuric disease, thrombocytopenia (Cvetković 2013)

Hypersensitivity: Angioedema, hypersensitivity reaction

Nervous system: Abnormal dreams, anxiety, depersonalization, depression, female sexual disorder, hypoesthesia, insomnia, malaise, male sexual disorder, pain, paresthesia, peripheral neuropathy, rigors, vertigo

Neuromuscular & skeletal: Arthralgia, arthropathy, asthenia, back pain, muscle cramps, myalgia, tremor

Ophthalmic: Conjunctivitis, diplopia, eye pain

Otic: Tinnitus

Respiratory: Dyspnea, epistaxis

Postmarketing:

Dermatologic: Dermatologic disorder (Schamberg's disease) (Schetz 2015), psoriasis (Song 2021), toxic epidermal necrolysis (Baetz 2011)

Endocrine and metabolic: Gynecomastia (Cornes 2001)

Hepatic: Cholestatic hepatitis (Egbuonu 2019; Zinsser 2004), hepatotoxicity (Demirci 2013; Hammerstrom 2015)

Renal: Acute interstitial nephritis (Ejaz 2000)

Contraindications

Hypersensitivity to levamlodipine, amlodipine, or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Hypotension: Symptomatic hypotension can occur; acute hypotension upon initiation is unlikely due to the gradual onset of action. BP must be lowered at a rate appropriate for the patient's clinical condition.

Disease-related concerns:

• Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may cause hypotension or reduce coronary perfusion, resulting in ischemia.

• Heart failure: Calcium channel blockers should be avoided whenever possible in patients with heart failure with reduced ejection fraction (AHA/ACC/HFSA [Heidenreich 2022]).

• Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose; titrate slowly in patients with severe hepatic impairment.

• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use amlodipine with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2020]).

Special populations:

• Older adult: Initiate at a lower dose in elderly patients.

Other warnings/precautions:

• Titration: Peak antihypertensive effect is delayed; dosage titration should occur after 7 to 14 days on a given dose.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral, as maleate:

Conjupri: 2.5 mg

Conjupri: 2.5 mg [DSC] [scored]

Conjupri: 5 mg

Conjupri: 5 mg [DSC] [scored]

Generic: 2.5 mg, 5 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Conjupri Oral)

2.5 mg (per each): $13.14

5 mg (per each): $15.34

Tablets (Levamlodipine Maleate Oral)

2.5 mg (per each): $2.80

5 mg (per each): $2.80

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Oral: May be administered without regard to food.

Administration: Pediatric

Oral: May be administered without regard to food.

Use: Labeled Indications

Hypertension: Treatment of hypertension, alone or in combination with other antihypertensive agents, in adults and pediatric patients ≥6 years of age.

Metabolism/Transport Effects

Substrate of CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP3A4 (weak)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. Risk C: Monitor therapy

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider therapy modification

Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor therapy

Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. Risk C: Monitor therapy

Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Risk X: Avoid combination

Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers. Risk C: Monitor therapy

CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. Risk C: Monitor therapy

CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Risk C: Monitor therapy

CYP3A4 Inducers (Moderate): May decrease the serum concentration of Levamlodipine. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Levamlodipine. Risk C: Monitor therapy

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Levamlodipine. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Levamlodipine. Risk C: Monitor therapy

Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers. Risk X: Avoid combination

Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers. Risk C: Monitor therapy

Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. Risk C: Monitor therapy

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Risk C: Monitor therapy

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. Risk C: Monitor therapy

Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. Risk C: Monitor therapy

Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Indoramin: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers. Risk C: Monitor therapy

Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. Risk C: Monitor therapy

Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant. Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors. Risk D: Consider therapy modification

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. Risk C: Monitor therapy

Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide. Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day. Risk D: Consider therapy modification

Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib. Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects. Risk D: Consider therapy modification

Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Lovastatin: Levamlodipine may increase the serum concentration of Lovastatin. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased. Risk C: Monitor therapy

Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine). Risk C: Monitor therapy

Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. Risk C: Monitor therapy

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. Risk C: Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider therapy modification

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Risk C: Monitor therapy

Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. Risk X: Avoid combination

Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. Risk C: Monitor therapy

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Red Yeast Rice: Levamlodipine may increase the serum concentration of Red Yeast Rice. Risk C: Monitor therapy

Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Simvastatin: Levamlodipine may increase the serum concentration of Simvastatin. Management: Limit simvastatin dose to 20 mg daily and monitor closely for signs and symptoms of rhabdomyolysis (eg, creatinine phosphokinase, muscle aches and pains) if coadministering with levamlodipine. Risk D: Consider therapy modification

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). Risk C: Monitor therapy

Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound). Management: Reduce the dose of protein bound sirolimus to 56 mg/m² when used concomitantly with a weak CYP3A4 inhibitor. Risk D: Consider therapy modification

Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). Risk C: Monitor therapy

Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). Risk C: Monitor therapy

Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. Risk C: Monitor therapy

Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. Risk C: Monitor therapy

Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant. Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg. Risk D: Consider therapy modification

Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. Risk C: Monitor therapy

Pregnancy Considerations

Amlodipine is a racemic mixture of levamlodipine and dextro amlodipine; levamlodipine is the pharmacologically active isomer. Amlodipine crosses the placenta (Morgan 2017; Morgan 2018).

Refer to the amlodipine monograph for additional information,

Breastfeeding Considerations

Amlodipine is present in breast milk.

Amlodipine is a racemic mixture of levamlodipine and dextro amlodipine; levamlodipine is the pharmacologically active isomer. Refer to the amlodipine monograph for additional information.

Monitoring Parameters

Heart rate; blood pressure.

Mechanism of Action

Amlodipine is a 1:1 racemic mixture of levamlodipine and dextro amlodipine; it has been demonstrated that levamlodipine is the pharmacologically active, antihypertensive isomer. Amlodipine is a dihydropyridine calcium channel blocker that exerts its effect by blocking the transmembrane influx of calcium ions primarily into vascular smooth muscle cells and to a lesser extent into cardiac muscle cells. It reduces peripheral vascular resistance and lowers BP by acting directly on vascular smooth muscle.

Pharmacokinetics (Adult Data Unless Noted)

Note: Amlodipine is a racemic mixture of levamlodipine and dextro amlodipine; levamlodipine is the pharmacologically active isomer. Refer to the amlodipine monograph for additional information.

Onset: Gradual.

Duration: ≥24 hours.

Protein binding: ~93%.

Metabolism: Hepatic (~90%) to inactive metabolites.

Bioavailability: 64% to 90%.

Half-life elimination: Terminal (biphasic): ~30 to 50 hours; increased with hepatic dysfunction.

Time to peak: 6 to 12 hours.

Excretion: Urine (10% of total dose as unchanged drug, 60% of total dose as metabolites).

Clearance: May be decreased in patients with hepatic insufficiency or moderate to severe heart failure; weight-adjusted clearance in children >6 years of age is similar to adults.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Hepatic function impairment: AUC may increase ~40% to 60%.

Elderly: AUC may increase ~40% to 60%.

Moderate to severe heart failure: AUC may increase ~40% to 60%.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(BD) Bangladesh: L Amlo | Lm;
(BR) Brazil: Atelop | Cor select | Novanlo;
(CN) China: Fu si duo | Jing rui xin | Levamlodipine besylate | Levoamlodipine maleate | Shi hui da | Shi mei li jian | Xing di | Xuan ning | Zuo yi;
(CO) Colombia: Artamlo | S-numlo;
(DO) Dominican Republic: Fendipres | S amapine;
(EC) Ecuador: Kairopine;
(ET) Ethiopia: Asomex;
(IN) India: Apruv | S Amlip | S amlosafe | S-amcard | S-amlong | S-numlo;
(KE) Kenya: Esem | Mylovasc | S amlo | S amlosafe | S-numlo | Samlo;
(KR) Korea, Republic of: Ambas | Ambp s | Amlospine s | Amlotension s | Amlovas | Ams | Amvesc s | Anydipine S | Ard s | Easytention | Emdipin s | Esarodip | Kairopine | Levodipine | Levotension | Melodipine s | Newamlos | Newdipine s | Nexdipine | Noma s | Notension | Novdipine s | Rovadipin s | S alodip | S amlodix | S amlomin | S amlosyl | S ampin | S lodipine | S lopine | S medy | S tension | S vapin | Sab | Sdipine | Siampin | Twotention | Z tension;
(NG) Nigeria: Mylovasc | S amlo | S odip;
(PH) Philippines: Ezlopin;
(PR) Puerto Rico: Conjupri;
(UA) Ukraine: Samlopin;
(UG) Uganda: S amlosafe;
(ZM) Zambia: Esem

Baetz BE, Patton ML, Guilday RE, Reigart CL, Ackerman BH. Amlodipine-induced toxic epidermal necrolysis. J Burn Care Res. 2011;32(5):e158-160. doi:10.1097/BCR.0b013e31822ac7be [PubMed 21772148]
Conjupri (levamlodipine) [prescribing information]. Ridgeland, MS: WraSer Pharmaceuticals; December 2021.
Cornes PG, Hole AC. Amlodipine gynaecomastia. Breast. 2001;10(6):544-545. doi:10.1054/brst.2001.0308 [PubMed 14965638]
Cvetković Z, Suvajdžić-Vuković N, Todorović Z, Panić M, Nešković A. Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature review. J Clin Pharm Ther. 2013;38(3):246-248. doi:10.1111/jcpt.12051 [PubMed 23442182]
Demirci H, Polat Z, Kantarcioglu M, Kekilli M, Uygun A, Bagci S. Short-term amlodipine induced liver injury: an extremely rare acute complication. Acta Gastroenterol Belg. 2013;76(4):441. [PubMed 24592551]
Egbuonu F, Fazal B, Atwan M, Davies A. Rare case of amlodipine induced hepatitis: a case report. J Med Therap. 2019:3;1-2. doi:10.15761/JMT.1000142
Ejaz AA, Fitzpatrick PM, Haley WE, Wasiluk A, Durkin AJ, Zachariah PK. Amlodipine besylate induced acute interstitial nephritis. Nephron. 2000;85(4):354-356. doi:10.1159/000045688 [PubMed 10940749]
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061. [PubMed 26934393]
Hammerstrom AE. Possible amlodipine-induced hepatotoxicity after stem cell transplant. Ann Pharmacother. 2015;49(1):135-139. doi:10.1177/1060028014552820 [PubMed 25239629]
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 [PubMed 35363499]
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003 [PubMed 33637192]
Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, Messerli FH. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270-1280. doi:10.1097/HJH.0b013e3283472643 [PubMed 21558959]
Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 7, 2023.
Morgan JL, Kogutt BK, Meek C et al. Pharmacokinetics of amlodipine besylate during pregnancy-how much infant exposure occurs? Am J Obstet Gynecol. 2017;216:S515-S516.
Morgan JL, Kogutt BK, Meek C, et al. Pharmacokinetics of amlodipine besylate at delivery and during lactation. Pregnancy Hypertens. 2018;11:77-80. doi: 10.1016/j.preghy.2018.01.002. [PubMed 29523279]
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045 [PubMed 33229116]
Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens. 2001;15(7):455-461. doi:10.1038/sj.jhh.1001201 [PubMed 11464254]
Pedrinelli R, Dell'Omo G, Melillo E, Mariani M. Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension. 2000;35(2):621-625. doi:10.1161/01.hyp.35.2.621 [PubMed 10679507]
Schetz D, Kocić I. A new adverse drug reaction--Schamberg's disease caused by amlodipine administration--a case report. Br J Clin Pharmacol. 2015;80(6):1477-1478. doi:10.1111/bcp.12742 [PubMed 26256559]
Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. Br J Clin Pharmacol. Published online October 5, 2021. doi:10.1111/bcp.15060 [PubMed 34611920]
Vukadinović D, Scholz SS, Messerli FH, Weber MA, Williams B, Böhm M, Mahfoud F. Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. J Hypertens. 2019;37(10):2093-2103. doi:10.1097/HJH.0000000000002145 [PubMed 31107359]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [published correction appears in Hypertension. 2018;71(6):e140-e144]. Hypertension. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. [PubMed 29133356]
Zinsser P, Meyer-Wyss B, Rich P. Hepatotoxicity induced by celecoxib and amlodipine. Swiss Med Wkly. 2004;134(13-14):201. [PubMed 15106034]

Topic 126414 Version 111.0

خرید پکیج

Levamlodipine: Drug information